Last Updated: August 2, 2026

ESZOPICLONE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Eszopiclone patents expire, and when can generic versions of Eszopiclone launch?

Eszopiclone is a drug marketed by Aurobindo Pharma, Chartwell Rx, Dr Reddys, Glenmark Pharms Ltd, Hetero Labs Ltd V, Hikma, Ipca Labs Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Orbion Pharms, Pharmobedient, Sun Pharm, and Teva. and is included in fourteen NDAs.

The generic ingredient in ESZOPICLONE is eszopiclone. There are twenty drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the eszopiclone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eszopiclone

A generic version of ESZOPICLONE was approved as eszopiclone by TEVA on May 23^rd, 2011.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ESZOPICLONE?
What are the global sales for ESZOPICLONE?
What is Average Wholesale Price for ESZOPICLONE?

Summary for ESZOPICLONE

US Patents:	0
Applicants:	14
NDAs:	14

Paragraph IV (Patent) Challenges for ESZOPICLONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUNESTA	Tablets	eszopiclone	1 mg, 2 mg and 3 mg	021476	10	2008-12-15

US Patents and Regulatory Information for ESZOPICLONE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	ESZOPICLONE	eszopiclone	TABLET;ORAL	091169-002	May 23, 2011	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Orbion Pharms	ESZOPICLONE	eszopiclone	TABLET;ORAL	091113-002	Jun 10, 2014	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mylan Pharms Inc	ESZOPICLONE	eszopiclone	TABLET;ORAL	091151-001	Mar 26, 2013	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Orbion Pharms	ESZOPICLONE	eszopiclone	TABLET;ORAL	091113-003	Jun 10, 2014	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.